CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Newsroom

Press releases and media contact.

Press releases

Get news alerts →
March 23, 2022
Pipeline
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
February 16, 2022
Pipeline
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
February 1, 2022
Pipeline
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus
January 12, 2022
Pipeline
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
January 4, 2022
Pipeline
PharmaTher Announces Publication of Research Data for KETABET™
December 21, 2021
Corporate
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022
December 20, 2021
Platform & partnering
PHARMATHER ENTERS INTO PROCESS DEVELOPMENT AGREEMENT WITH LTS LOHMANN FOR KETAMINE MICRONEEDLE PATCH
December 14, 2021
Pipeline
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
November 30, 2021
Pipeline
PharmaTher Granted New Japanese Patent for KETABET™  (Ketamine Combination Formulation), Strengthening Global Patent Portfolio
November 24, 2021
Pipeline
PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus
November 11, 2021
Pipeline
PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch
November 3, 2021
Platform & partnering
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch
November 1, 2021
Pipeline
PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics
October 27, 2021
Pipeline
World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor
October 27, 2021
Financial
PharmaTher Provides Busines Update and Releases Financial Results for the First Quarter of Fiscal 2022
October 19, 2021
Pipeline
PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products
October 13, 2021
Pipeline
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
October 6, 2021
Pipeline
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
September 29, 2021
Pipeline
PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
September 28, 2021
Financial
PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

All PharmaTher press releases since October 2020, newest first.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.